Foreign-Trade Zone (FTZ) 99-Wilmington, Delaware, Notification of Proposed Production Activity AstraZeneca Pharmaceuticals, LP (Pharmaceutical Products), Newark, Delaware, 10771 [2022-03953]
Download as PDF
<![CDATA[
lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 87, No. 38 / Friday, February 25, 2022 / Notices
representative samples using
transparent methodology. The BTOS
will produce data continuously, in part
as a response to feedback on the SBPS
that longer time series would have been
useful to contextualize the pandemic
impact. Continuous data will allow for
the measurement of economic trends
during all phases of the business cycle
as well as during times of economic and
other emergencies. The BTOS will
uniquely provide the ability to produce
these data and associated measures of
quality.
The BTOS data series will provide
insight on the state of the economy,
prior to and during an event (including
but not limited to natural disasters or
economic crises) and will assist in
monitoring the recovery from the event.
It will also be useful in understanding
aggregate and subaggregate changes in
economic trends throughout the
business cycle. BTOS data may be used
by elected officials, government
program officials, policy makers,
industry leaders, economic and social
analysts, business entrepreneurs,
business and economic news
organizations, and domestic and foreign
researchers in academia, business, and
government.
The BTOS will allow for a large
number of data products that are
complementary to the Census Bureau’s
existing monthly and quarterly
economic indicator programs which
provide estimates of contemporaneous
economic activity at the national sector
level. The BTOS will produce
complementary disaggregate
contemporaneous data as well as data
that reflect the outlook of businesses.
The BTOS will be complementary to the
Census Bureau’s existing annual
programs, serving as a platform through
which trends and data gaps may first be
identified for subsequent inclusion in
annual programs.
The BTOS instrument will include
core and supplemental content. Core
content will form the basis of the
instrument and run continuously; core
content will include measures of
economic activity that are applicable
across all non-farm sectors and are
important across the business cycle and
during economic or other emergencies.
Supplemental content will be included
on the instrument with a regular
periodicity and will be designed to
provide urgently needed data on an
emerging or current issue.
Core concepts for the BTOS will be
selected based on research and analysis
conducted during the SBPS, stakeholder
feedback, and the ability to collect
complementary items on monthly,
VerDate Sep<11>2014
16:44 Feb 24, 2022
Jkt 256001
quarterly, annual, or census programs to
provide context and benchmarking.
Initially, all data products will be
accessible through the Census Bureau’s
Experimental Data Products site.
Experimental data products are clearly
identified and include methodology and
supporting research with their release.
Affected Public: Business or other forprofit organizations.
Frequency: Bi-weekly.
Respondent’s Obligation: Voluntary.
Legal Authority: Title 13 U.S.C.,
Sections 131 and 182.
This information collection request
may be viewed at www.reginfo.gov.
Follow the instructions to view the
Department of Commerce collections
currently under review by OMB.
Written comments and
recommendations for the proposed
information collection should be
submitted within 30 days of the
publication of this notice on the
following website www.reginfo.gov/
public/do/PRAMain. Find this
particular information collection by
selecting ‘‘Currently under 30-day
Review—Open for Public Comments’’ or
by using the search function and
entering the title of the collection.
Sheleen Dumas,
Department PRA Clearance Officer, Office of
the Chief Information Officer, Commerce
Department.
[FR Doc. 2022–04060 Filed 2–24–22; 8:45 am]
BILLING CODE 3510–07–P
DEPARTMENT OF COMMERCE
Foreign-Trade Zones Board
[B–05–2022]
Foreign-Trade Zone (FTZ) 99—
Wilmington, Delaware, Notification of
Proposed Production Activity
AstraZeneca Pharmaceuticals, LP
(Pharmaceutical Products), Newark,
Delaware
AstraZeneca Pharmaceuticals, LP
submitted a notification of proposed
production activity to the FTZ Board
(the Board) for its facility in Newark,
Delaware within Subzone 99D. The
notification conforming to the
requirements of the Board’s regulations
(15 CFR 400.22) was received on
February 16, 2022.
Pursuant to 15 CFR 400.14(b), FTZ
production activity would be limited to
the specific foreign-status materials and
specific finished products described in
the submitted notification (summarized
below) and subsequently authorized by
the Board. The benefits that may stem
from conducting production activity
PO 00000
Frm 00008
Fmt 4703
Sfmt 4703
10771
under FTZ procedures are explained in
the background section of the Board’s
website—accessible via www.trade.gov/
ftz. The proposed finished products and
materials would be added to the
production authority that the Board
previously approved for the operation,
as reflected on the Board’s website.
The proposed finished products
include: BRILINTA (ticagrelor) tablets;
LYNPARZA (olaparib) tablets;
SEROQUEL IR (quetiapine fumarate)
tablets; and, SEROQUEL XR (quetiapine
fumarate) tablets (duty-free).
The proposed foreign-status materials
include: Anastrozole active
pharmaceutical ingredient (API);
olaparib API; quetiapine fumarate API;
and, ticagrelor API (duty rates 6.5%).
The request indicates that olaparib API
and ticagrelor API are subject to duties
under Section 301 of the Trade Act of
1974 (Section 301), depending on the
country of origin. The applicable
Section 301 decisions require subject
merchandise to be admitted to FTZs in
privileged foreign status (19 CFR
146.41).
Public comment is invited from
interested parties. Submissions shall be
addressed to the Board’s Executive
Secretary and sent to: ftz@trade.gov. The
closing period for their receipt is April
6, 2022.
A copy of the notification will be
available for public inspection in the
‘‘Online FTZ Information System’’
section of the Board’s website.
For further information, contact
Christopher Wedderburn at
Chris.Wedderburn@trade.gov.
Dated: February 18, 2022.
Andrew McGilvray,
Executive Secretary.
[FR Doc. 2022–03953 Filed 2–24–22; 8:45 am]
BILLING CODE 3510–DS–P
DEPARTMENT OF COMMERCE
Bureau of Industry and Security
Transportation and Related Equipment
Technical Advisory Committee; Notice
of Partially Closed Meeting
The Transportation and Related
Equipment Technical Advisory
Committee will meet on March 16,
2022, at 11:30 a.m., Eastern Standard
Time, via teleconference. The
Committee advises the Office of the
Assistant Secretary for Export
Administration with respect to technical
questions that affect the level of export
controls applicable to transportation
and related equipment or technology.
E:\FR\FM\25FEN1.SGM
25FEN1
]]>Agencies
[Federal Register Volume 87, Number 38 (Friday, February 25, 2022)]
[Notices]
[Page 10771]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-03953]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Foreign-Trade Zones Board
[B-05-2022]
Foreign-Trade Zone (FTZ) 99--Wilmington, Delaware, Notification
of Proposed Production Activity AstraZeneca Pharmaceuticals, LP
(Pharmaceutical Products), Newark, Delaware
AstraZeneca Pharmaceuticals, LP submitted a notification of
proposed production activity to the FTZ Board (the Board) for its
facility in Newark, Delaware within Subzone 99D. The notification
conforming to the requirements of the Board's regulations (15 CFR
400.22) was received on February 16, 2022.
Pursuant to 15 CFR 400.14(b), FTZ production activity would be
limited to the specific foreign-status materials and specific finished
products described in the submitted notification (summarized below) and
subsequently authorized by the Board. The benefits that may stem from
conducting production activity under FTZ procedures are explained in
the background section of the Board's website--accessible via
www.trade.gov/ftz. The proposed finished products and materials would
be added to the production authority that the Board previously approved
for the operation, as reflected on the Board's website.
The proposed finished products include: BRILINTA (ticagrelor)
tablets; LYNPARZA (olaparib) tablets; SEROQUEL IR (quetiapine fumarate)
tablets; and, SEROQUEL XR (quetiapine fumarate) tablets (duty-free).
The proposed foreign-status materials include: Anastrozole active
pharmaceutical ingredient (API); olaparib API; quetiapine fumarate API;
and, ticagrelor API (duty rates 6.5%). The request indicates that
olaparib API and ticagrelor API are subject to duties under Section 301
of the Trade Act of 1974 (Section 301), depending on the country of
origin. The applicable Section 301 decisions require subject
merchandise to be admitted to FTZs in privileged foreign status (19 CFR
146.41).
Public comment is invited from interested parties. Submissions
shall be addressed to the Board's Executive Secretary and sent to:
[email protected]. The closing period for their receipt is April 6, 2022.
A copy of the notification will be available for public inspection
in the ``Online FTZ Information System'' section of the Board's
website.
For further information, contact Christopher Wedderburn at
[email protected].
Dated: February 18, 2022.
Andrew McGilvray,
Executive Secretary.
[FR Doc. 2022-03953 Filed 2-24-22; 8:45 am]
BILLING CODE 3510-DS-P
